|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006826,
umls-concept:C0029246,
umls-concept:C0030705,
umls-concept:C0035168,
umls-concept:C0040808,
umls-concept:C0087111,
umls-concept:C0206012,
umls-concept:C0239307,
umls-concept:C0278488,
umls-concept:C0876994,
umls-concept:C1096776,
umls-concept:C1274040,
umls-concept:C1515273,
umls-concept:C1705313
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2002-12-19
|
|
pubmed:abstractText |
The potential cardiotoxicity of the doxorubicin-paclitaxel regimen, when paclitaxel is given shortly after the end of the anthracycline infusion, is an issue of concern, as suggested by small single institution Phase II studies.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
pubmed-author:BiganzoliLauraL,
pubmed-author:BruningPeterP,
pubmed-author:ColemanRobert ERE,
pubmed-author:CuferTanjaT,
pubmed-author:DelhayeFrançoisF,
pubmed-author:DuchateauLucL,
pubmed-author:HamiltonAA,
pubmed-author:MilerGG,
pubmed-author:NooijMarianneM,
pubmed-author:PiccartMartineM,
pubmed-author:RapoportBernardoB,
pubmed-author:SulkesAaronA
|
|
pubmed:copyrightInfo |
Copyright 2003 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
97
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
40-5
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12491503-Adenocarcinoma,
pubmed-meshheading:12491503-Adult,
pubmed-meshheading:12491503-Aged,
pubmed-meshheading:12491503-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12491503-Breast Neoplasms,
pubmed-meshheading:12491503-Cyclophosphamide,
pubmed-meshheading:12491503-Disease Progression,
pubmed-meshheading:12491503-Disease-Free Survival,
pubmed-meshheading:12491503-Doxorubicin,
pubmed-meshheading:12491503-Female,
pubmed-meshheading:12491503-Follow-Up Studies,
pubmed-meshheading:12491503-Heart,
pubmed-meshheading:12491503-Humans,
pubmed-meshheading:12491503-Middle Aged,
pubmed-meshheading:12491503-Paclitaxel,
pubmed-meshheading:12491503-Risk Factors,
pubmed-meshheading:12491503-Safety,
pubmed-meshheading:12491503-Survival Rate,
pubmed-meshheading:12491503-Treatment Outcome
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European Organization for Research and Treatment of Cancer multicenter trial.
|
|
pubmed:affiliation |
IDBBC Unit, EORTC-IDBBC, Jules Bordet Institute, Boulevard de Waterloo 121, 7th floor, 1000 Brussels, Belgium. laura.biganzoli@bordet.be
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
